Local vasoregulative interventions impact drug concentrations in the skin after topical laser-assisted delivery.
5-fluorouracil
fractional ablative CO2 laser
in vivo skin
optical coherence tomography
topical laser-assisted drug delivery
Journal
Lasers in surgery and medicine
ISSN: 1096-9101
Titre abrégé: Lasers Surg Med
Pays: United States
ID NLM: 8007168
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
revised:
09
05
2022
received:
01
03
2022
accepted:
09
05
2022
pubmed:
21
5
2022
medline:
16
12
2022
entrez:
20
5
2022
Statut:
ppublish
Résumé
The ability of ablative fractional lasers (AFL) to enhance topical drug uptake is well established. After AFL delivery, however, drug clearance by local vasculature is poorly understood. Modifications in vascular clearance may enhance AFL-assisted drug concentrations and prolong drug dwell time in the skin. Aiming to assess the role and modifiability of vascular clearance after AFL-assisted delivery, this study examined the impact of vasoregulative interventions on AFL-assisted 5-fluorouracil (5-FU) concentrations in in vivo skin. 5-FU uptake was assessed in intact and AFL-exposed skin in a live pig model. After fractional CO Compared to intact skin, AFL facilitated a prompt peak in 5-FU delivery that remained elevated up to 4 hours (1500 μm: 1.5 vs. 31.8 ng/ml [1 hour, p = 0.002]; 5.3 vs. 14.5 ng/ml [4 hours, p = 0.039]). However, AFL's impact was transient, with 5-FU concentrations comparable to intact skin at later time points. Overall, vasoregulative intervention with brimonidine or PDL led to significantly higher peak 5-FU concentrations, prolonging the drug's dwell time in the skin versus AFL delivery alone. As such, brimonidine and PDL led to twofold higher 5-FU concentrations than AFL alone in both skin layers by 1 hour (e.g., 500 μm: 107 ng/ml [brimonidine]; 96.9 ng/ml [PDL], 46.6 ng/ml [AFL alone], p ≤ 0.024), and remained significantly elevated at 4 hours (p ≤ 0.024). A similar pattern was observed for epinephrine, although trends remained nonsignificant (p ≥ 0.09). Prolonged 5-FU delivery was provided by PDL, resulting in sustained drug deposition compared to AFL alone at both 48 and 72 hours in the superficial skin layer (p ≤ 0.024). Supporting drug delivery findings, OCT revealed that increases in local blood flow after AFL were mitigated in test areas also exposed to PDL, brimonidine, or epinephrine, with PDL providing the greatest, sustained reduction in flow over 48 hours. Vasoregulative intervention in conjunction with AFL-assisted delivery enhances and prolongs 5-FU deposition in in vivo skin.
Identifiants
pubmed: 35593006
doi: 10.1002/lsm.23558
pmc: PMC9675883
mid: NIHMS1808254
doi:
Substances chimiques
Fluorouracil
U3P01618RT
Brimonidine Tartrate
4S9CL2DY2H
Epinephrine
YKH834O4BH
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1288-1297Subventions
Organisme : NIBIB NIH HHS
ID : P41 EB015903
Pays : United States
Informations de copyright
© 2022 The Authors. Lasers in Surgery and Medicine published by Wiley Periodicals LLC.
Références
Facial Plast Surg Clin North Am. 2017 Feb;25(1):105-117
pubmed: 27888888
Adv Drug Deliv Rev. 2020 Jan 1;153:185-194
pubmed: 31923431
Expert Opin Drug Deliv. 2016;13(5):755-68
pubmed: 26808472
J Control Release. 2007 Mar 12;118(1):18-26
pubmed: 17254662
Drug Deliv. 2018 Nov;25(1):1877-1885
pubmed: 30474430
Lasers Med Sci. 2022 Mar;37(2):1273-1282
pubmed: 34351564
Semin Cutan Med Surg. 2017 Dec;36(4):192-201
pubmed: 29224037
Opt Express. 2004 Oct 4;12(20):4822-8
pubmed: 19484034
Lasers Surg Med. 2021 Jan;53(1):119-128
pubmed: 32960987
Dermatol Surg. 2016 Sep;42(9):1050-3
pubmed: 27359199
Lasers Surg Med. 2014 Apr;46(4):281-9
pubmed: 24500855
Dermatol Surg. 2017 May;43(5):615-624
pubmed: 28195845
Skin Res Technol. 2010 Aug;16(3):259-64
pubmed: 20636992
Expert Opin Drug Deliv. 2017 Mar;14(3):307-317
pubmed: 27835937
Clin Pharmacol. 2016 Oct 19;8:163-176
pubmed: 27799831
Lasers Surg Med. 2022 Dec;54(10):1288-1297
pubmed: 35593006
Lasers Surg Med. 2018 Jan;50(1):20-27
pubmed: 29154501
Dermatologica. 1979;158(5):368-72
pubmed: 437226
Anesthesiology. 1999 Oct;91(4):962-8
pubmed: 10519498
Eur J Clin Pharmacol. 1992;43(6):625-8
pubmed: 1493844
J Am Acad Dermatol. 2015 Mar;72(3):558-60
pubmed: 25687314
Skin Pharmacol Physiol. 2005 Mar-Apr;18(2):55-74
pubmed: 15767767
Patient Prefer Adherence. 2017 Jul 06;11:1143-1150
pubmed: 28740369
J Pharm Sci. 1994 Jun;83(6):783-91
pubmed: 9120806
J Am Acad Dermatol. 2016 May;74(5):981-1004
pubmed: 26936299
Acta Anaesthesiol Scand. 1991 Apr;35(3):208-15
pubmed: 2038927
Biomed Opt Express. 2014 Oct 07;5(11):3822-32
pubmed: 25426313
Anat Rec. 1969 Apr;163(4):517-24
pubmed: 5776879
J Am Acad Dermatol. 2014 Jun;70(6):965.e1-12; quiz 977-8
pubmed: 24831324
Adv Drug Deliv Rev. 2020 Jan 1;153:169-184
pubmed: 31628965
Lasers Surg Med. 2022 Jan;54(1):113-120
pubmed: 34865224
Arch Dermatol. 1978 Jul;114(7):1021-2
pubmed: 686718
J Am Acad Dermatol. 2019 Apr;80(4):947-956
pubmed: 30267719
Dermatol Surg. 2020 Aug;46(8):1045-1053
pubmed: 32049702
Int J Pharm. 2005 Jan 20;288(2):227-33
pubmed: 15620862
J Control Release. 2018 Apr 10;275:242-253
pubmed: 29454062
Lasers Surg Med. 2021 Jan;53(1):162-170
pubmed: 33161610
Lasers Surg Med. 2012 Feb;44(2):168-74
pubmed: 22302761